enzastaurin has been researched along with pemetrexed in 12 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (pemetrexed) | Trials (pemetrexed) | Recent Studies (post-2010) (pemetrexed) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 2,469 | 657 | 1,695 |
| Protein | Taxonomy | enzastaurin (IC50) | pemetrexed (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.1 | |
| Dihydrofolate reductase | Homo sapiens (human) | 4.0309 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 2.3 | |
| Thymidylate synthase | Homo sapiens (human) | 8.1787 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 2.3 | |
| Folate receptor beta | Homo sapiens (human) | 0.2585 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2417 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.0342 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.07 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0928 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.655 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.0229 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Alice Miller, M; Pearce, HL | 1 |
| Blatter, J; Eismann, U; Hanauske, AR; Lahn, MM; Ma, D; Oberschmidt, O; Schulz, L; Struck, S | 1 |
| Boehm, A; Dietz, A; Giannis, A; Mozet, C; Wichmann, G | 1 |
| Giovannetti, E; Graff, JR; Peters, GJ; Sigmond, J; Smid, K; Tekle, C | 1 |
| Giaccone, G; Graefe, T; Hanauske, AR; Kuenen, B; Lahn, M; McNealy, P; Musib, LC; Thornton, D; Weigang-Köhler, K; Yilmaz, E | 1 |
| Giaccone, G; Giovannetti, E; Hanauske, AR; Honeywell, R; Kuenen, B; Peters, GJ; Sigmond, J; Tekle, C | 1 |
| Barata, F; Barlesi, F; Bearz, A; Bepler, G; Chiappori, A; Chouaki, N; Iscoe, N; Liepa, AM; Park, K; Reck, M; Scagliotti, G; Soria, JC; von Pawel, J; Wagle, A; Zhao, YD | 1 |
| Baldwin, JR; Koshiji, M; Kunitoh, H; Murakami, H; Nakamura, Y; Nokihara, H; Ohe, Y; Shukuya, T; Takahashi, T; Tamura, T; Tanai, C; Yamamoto, N | 1 |
| Bradford, D; Bufill, J; Casey, EM; Fisher, W; Hanna, N; Harb, W; Latz, JE; Li, X; Nattam, S; Patel, J; Wu, J | 1 |
| Asmar, L; Barrera, D; Bromund, J; Choksi, JK; Couch, LS; Jotte, R; Kocs, DM; Obasaju, CK; Patt, DA; Peng, G; Periman, PO; Pritchard, S; Raju, RN; Rousey, SR; Schlossberg, HR; Socinski, MA; Stinchcombe, T; Treat, J; Wang, Y; Weissman, CH | 1 |
| Chouaki, N; Eschbach, C; Kennedy, L; Ramlau, R; Reck, M; San Antonio, B; Szczesna, A; Vansteenkiste, J; Visseren-Grul, C; von Pawel, J | 1 |
2 review(s) available for enzastaurin and pemetrexed
| Article | Year |
|---|---|
Current aspects of targeted therapy in head and neck tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Folic Acid Antagonists; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Indoles; Pemetrexed; Protein-Tyrosine Kinases | 2008 |
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Pemetrexed | 2010 |
6 trial(s) available for enzastaurin and pemetrexed
| Article | Year |
|---|---|
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Glutamates; Guanine; Humans; Indoles; Male; Middle Aged; Neoplasms; Pemetrexed | 2009 |
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Female; Folic Acid; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Salvage Therapy; Survival Rate; Vitamin B 12 | 2010 |
A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Pemetrexed; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life | 2010 |
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Placebos | 2012 |
4 other study(ies) available for enzastaurin and pemetrexed
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Industry; Gemcitabine; Glutamates; Guanine; History, 20th Century; Humans; Indoles; Neoplasms; Pemetrexed; United States | 2005 |
Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Folic Acid Antagonists; Glutamates; Guanine; Humans; Indoles; Pemetrexed; Protein Kinase C; Protein Kinase C beta; Thyroid Neoplasms | 2005 |
Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Drug Synergism; Folic Acid Antagonists; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Pemetrexed; Phosphorylation; Polymerase Chain Reaction; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2008 |